Neoadjuvant hormonal therapy plus surgery for prostate cancer. The MSKCC experience

This article reviews the current status of neoadjuvant hormonal therapy (NHT) in the treatment of clinically localized prostate cancer. Although significant increases in the organ confined rate and similar marked decreases in the positive margin rate are found in patients receiving NHT, to date no difference in disease free survival rate, as determined by PSA values, can be shown. However, there is a suggestion (P = 10 ng/ ml when treated with NHT compared with controls. Given the prolonged natural history of prostate cancer, longer follow-up will be required before the value of NHT can be established.